Is Adeshwar Meditex overvalued or undervalued?

As of 13 October 2025, the valuation grade for Adeshwar Meditex has moved from attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 13.33, an EV to EBITDA of 8.52, and a ROCE of 8.30%.
In comparison to its peers, Adeshwar Meditex's valuation appears reasonable against companies like Poly Medicure, which has a PE ratio of 52.85 and an EV to EBITDA of 39.23, indicating a significantly higher valuation. Another peer, Blue Jet Health, also shows a high PE of 32.02. While Adeshwar Meditex has underperformed the Sensex over the past year with a return of -10.07% compared to the Sensex's 1.16%, its current valuation suggests it is neither undervalued nor overvalued, but rather fairly positioned in the market.